Tysabri 300mg Injection

Tysabri 300mg Injection contains the active ingredient natalizumab. It is a monoclonal antibody medicine used to treat multiple sclerosis (MS) and Crohn's disease. Multiple sclerosis is a long-term autoimmune disorder that affects the central nervous system, disrupting communication between the brain and the rest of the body. Crohn's disease is a chronic inflammatory bowel condition that affects the digestive tract. Tysabri 300mg Injection works by blocking the movement of specific immune cells responsible for inflammation, helping reduce damage to the central nervous system in MS and controlling inflammation in the intestines in Crohn's disease. By effectively controlling disease activity, Tysabri 300mg Injection may improve quality of life by relieving symptoms, reducing the frequency of relapses, and potentially slowing the progression of disability. Tysabri 300mg Injection may trigger hypersensitivity reactions in some individuals. Patients with a known allergy to natalizumab or any of its ingredients should avoid using this medicine, and those at increased risk should undergo appropriate evaluation before treatment. This medicine is contraindicated in patients with a history of progressive multifocal leukoencephalopathy (PML) or those who test positive for the JC virus, as they have a greater risk of developing PML during therapy. It should also not be used in patients with active infections, particularly severe or opportunistic infections. The safety and efficacy of Tysabri 300mg Injection have not been fully established in children and adolescents; therefore, its use is generally not recommended in the pediatric population.

Tysabri 300mg injection is used to treat the following: Multiple sclerosis (MS) Crohn's disease.

Tysabri 300mg injection is a monoclonal antibody that works by targeting a protein called α4-integrin on certain immune cells. By binding to α4-integrin, it prevents these immune cells from crossing the blood-brain barrier in multiple sclerosis or migrating into the gut lining in Crohn's disease. This action reduces inflammation and helps protect the central nervous system in MS, leading to fewer relapses and slowed disease progression. Overall, its mechanism of action modulates the immune response, providing therapeutic benefits in treating multiple sclerosis and Crohn's disease.

Tysabri 300mg injection should be taken exactly as prescribed by a healthcare professional. The route of administration for this medication is intravenous (IV) infusion. The medication is delivered directly into the bloodstream through a vein. It is not available in oral form or as a subcutaneous injection.

Tysabri 300mg injection causes some side effects like all medications, although not everyone will experience them. Serious: Progressive multifocal leukoencephalopathy (PML) Infusion reactions Liver damage Infections Hypersensitivity Common: Headache Fatigue Nausea Upper respiratory tract infections (common cold) Urinary tract infections

For Tysabri 300mg injection safe use close monitoring for signs of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection, as well as hypersensitivity reactions during or after infusion. Regular liver function tests should be performed to detect any liver damage. Patients should be vigilant for signs of infections, and concomitant use with other immunomodulatory medications should be carefully considered. Prior screening for hepatitis B virus (HBV) is recommended, and live vaccines should not be administered during treatment. Pregnant or breastfeeding individuals should consult their healthcare provider before starting or continuing this medication. It is essential to discuss all medical conditions and medications with the healthcare provider to ensure the safe and appropriate use of these medications and to address any potential risks.